by secretome | May 23, 2023 | Investors, News
BALTIMORE, MD., June 10, 2021 — NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and other...
by secretome | May 23, 2023 | Investors, News
BALTIMORE–(BUSINESS WIRE)–NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and...
by secretome | May 16, 2023 | Investors, News
[DALLAS, TX – May 12, 2023] — Secretome Therapeutics, a pioneering biotechnology company focused on developing regenerative cell therapies, is pleased to announce its participation in the prestigious ISSCR 2023 Annual Meeting, held at the Boston Convention and...
by secretome | Oct 4, 2022 | News, Uncategorized
Secretome Therapeutics, a preclinical company developing novel therapies derived from neonatal mesenchymal stem cells, today announced the appointment of Angela Shen, M.D., M.B.A, to its Board of Directors. Dr. Shen is currently the Vice President, Strategic...
by Sudhish Sharma | Jun 17, 2022 | Journals, Uncategorized
Abstract Gunasekaran et al demonstrate that human neonatal Mesenchymal Stem Cells (nMSCs) evade from macrophage mediated phagocytosis via increased CD47 expression and to promote functional recovery by secretion of exosomes and independent cytokines. The increased...
by secretome | Sep 10, 2019 | News, Uncategorized
The Maryland Stem Cell Research Commission (Commission) has approved funding to its first round of fiscal year 2020 recipients for a total of $1,351,400. The Commission has also announced new leadership with the election of a new chair and vice chair to serve for the...
by Sudhish Sharma | May 22, 2019 | Journals, Uncategorized
Abstract The stem cell field is hindered by its inability to noninvasively monitor transplanted cells within the target organ in a repeatable, time-sensitive, and condition-specific manner. We hypothesized that quantifying and characterizing transplanted cell–derived...
by Sudhish Sharma | Jul 6, 2018 | Journals, Uncategorized
Abstract Hypoplastic left heart syndrome is a type of congenital heart disease characterized by underdevelopment of the left ventricle, outflow tract, and aorta. The condition is fatal if aggressive palliative operations are not undertaken, but even after the complete...
by Sudhish Sharma | Apr 2, 2018 | Journals, Uncategorized
Abstract One of the most complex forms of congenital heart disease (CHD) involving single ventricle physiology is hypoplastic left heart syndrome (HLHS), characterized by underdevelopment of the left ventricle (LV), mitral and aortic valves, and narrowing of the...
by Sudhish Sharma | Jan 10, 2018 | Journals, Uncategorized
Abstract Pregestational maternal diabetes induces congenital heart defects (CHDs). Cardiac dysfunction after palliative surgical procedures contributes to the high mortality of CHD patients. Autologous or allogeneic stem cell therapies are effective for improving...
